Diego Díaz-García, Medical Oncologist, CEO, Founder at CánCare – High Specialty in Oncology, shared on X:
“Advances in drug design, biomarker selection, and understanding of resistance mechanisms are renewing interest in targeting the PI3K/AKT/mTOR pathway. More selective inhibitors and rational combinations may improve efficacy while limiting toxicity.”
Title: A renaissance in targeting the PI3K/AKT/mTOR pathway
Authors: Sarah E. Conduit, Neil Vasan, Jennifer R. Brown, Matthew W. D. Perry, Bart Vanhaesebroeck
Read the full article on Nature Reviews Drug Discovery.
